E L Saenko|S W Pipe - JoVE Visualize

Showing results (71-80 of 85) with videos related to

Pageof 9

Sort By:

Thrombosis and Haemostasis|February 12, 1998

Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitorsY Sawamoto, R Prescott, D Zhong, et al.

British Journal of Haematology|May 31, 2001

Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRM(-)) and G1948D (CRM(r))D David, E L Saenko, I M Santos, et al.

Immunological Investigations|March 1, 1994

Modulatory effects of ceruloplasmin on lymphocytes, neutrophils and monocytes of patients with altered immune statusE L Saenko, O V Skorobogat'ko, P Tarasenko, et al.

Blood|May 15, 1997

The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study GroupsR Prescott, H Nakai, E L Saenko, et al.

Journal of Thrombosis and Haemostasis : JTH|November 20, 2008

Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin timeA Cuker, B Ptashkin, B A Konkle, et al.

Haemophilia : the Official Journal of the World Federation of Hemophilia|March 12, 2002

Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their actionE L Saenko, N M Ananyeva, D V Kouiavskaia, et al.

Haemophilia : the Official Journal of the World Federation of Hemophilia|March 21, 2009

Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia AL A Valentino, M Recht, J Dipaola, et al.

Haemophilia : the Official Journal of the World Federation of Hemophilia|March 2, 2016

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxisL A Valentino, S W Pipe, P W Collins, et al.

The Journal of Biological Chemistry|October 16, 1999

Role of factor VIII C2 domain in factor VIII binding to factor XaK Nogami, M Shima, K Hosokawa, et al.

Blood|February 7, 2001

Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysisK Nogami, M Shima, J C Giddings, et al.

Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:

Pageof 9

Thrombosis and Haemostasis|February 12, 1998

Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitorsY Sawamoto, R Prescott, D Zhong, et al.

British Journal of Haematology|May 31, 2001

Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRM(-)) and G1948D (CRM(r))D David, E L Saenko, I M Santos, et al.

Immunological Investigations|March 1, 1994

Modulatory effects of ceruloplasmin on lymphocytes, neutrophils and monocytes of patients with altered immune statusE L Saenko, O V Skorobogat'ko, P Tarasenko, et al.

Blood|May 15, 1997

The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study GroupsR Prescott, H Nakai, E L Saenko, et al.

Journal of Thrombosis and Haemostasis : JTH|November 20, 2008

Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin timeA Cuker, B Ptashkin, B A Konkle, et al.

Haemophilia : the Official Journal of the World Federation of Hemophilia|March 12, 2002

Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their actionE L Saenko, N M Ananyeva, D V Kouiavskaia, et al.

Haemophilia : the Official Journal of the World Federation of Hemophilia|March 21, 2009

Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia AL A Valentino, M Recht, J Dipaola, et al.

Haemophilia : the Official Journal of the World Federation of Hemophilia|March 2, 2016

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxisL A Valentino, S W Pipe, P W Collins, et al.

The Journal of Biological Chemistry|October 16, 1999

Role of factor VIII C2 domain in factor VIII binding to factor XaK Nogami, M Shima, K Hosokawa, et al.

Blood|February 7, 2001

Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysisK Nogami, M Shima, J C Giddings, et al.

Pageof 9